全文获取类型
收费全文 | 5599篇 |
免费 | 548篇 |
国内免费 | 132篇 |
专业分类
6279篇 |
出版年
2023年 | 49篇 |
2022年 | 105篇 |
2021年 | 184篇 |
2020年 | 111篇 |
2019年 | 129篇 |
2018年 | 142篇 |
2017年 | 93篇 |
2016年 | 167篇 |
2015年 | 327篇 |
2014年 | 339篇 |
2013年 | 410篇 |
2012年 | 491篇 |
2011年 | 438篇 |
2010年 | 251篇 |
2009年 | 210篇 |
2008年 | 308篇 |
2007年 | 247篇 |
2006年 | 243篇 |
2005年 | 227篇 |
2004年 | 199篇 |
2003年 | 171篇 |
2002年 | 167篇 |
2001年 | 107篇 |
2000年 | 121篇 |
1999年 | 108篇 |
1998年 | 63篇 |
1997年 | 49篇 |
1996年 | 35篇 |
1995年 | 35篇 |
1994年 | 43篇 |
1993年 | 41篇 |
1992年 | 70篇 |
1991年 | 56篇 |
1990年 | 45篇 |
1989年 | 55篇 |
1988年 | 50篇 |
1987年 | 35篇 |
1986年 | 39篇 |
1985年 | 30篇 |
1984年 | 50篇 |
1983年 | 27篇 |
1982年 | 27篇 |
1981年 | 22篇 |
1980年 | 15篇 |
1979年 | 27篇 |
1978年 | 24篇 |
1977年 | 20篇 |
1975年 | 16篇 |
1974年 | 9篇 |
1971年 | 11篇 |
排序方式: 共有6279条查询结果,搜索用时 15 毫秒
931.
932.
Giovanni Mantovani Vittorio Gebbia Mario Airoldi Cesare Bumma Paolo Contu Alessandro Bianchi Massimo Ghiani Daniela Dessì Elena Massa Luigi Curreli Biancarosa Lampis Paola Lai Carlo Mulas Antonio Testa Ernesto Proto Gabrio Cadeddu Giorgio Tore 《Cancer immunology, immunotherapy : CII》1998,47(3):149-156
We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical
response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interleukin-2
(rIL-2) in patients with advanced (stage III–IV) head and neck squamous-cell carcinoma (HNSCC). Regimen A was the classical
Al Sarraf treatment: 100 mg/m2 cisplatin i.v. on day 1 plus 1000 mg m−2 day−1 5-FU on days 1–5 as a continuous infusion. Regimen B was the same as regimen A plus 4.5 MIU/day rIL-2 s.c. on days 8–12 and
15–19. Treatment was repeated every 3 weeks for three cycles. A total of 33 patients were enrolled in the study; 30 were evaluable
for toxicity and 28 for response. Seventeen patients were assigned to group A and 16 were assigned to group B. Three patients
(20%) of group A and 4 (31%) of group B had a complete response, 9 patients (60%) of group A and 6 (46%) of group B had a
partial response, with an overall response rate of 12 patients (80%) for group A and 10 patients (77%) for group B. Two patients
(13%) of group A and 3 patients (23%) group B had stable disease; 1 patient (7%) of group A had progressive disease. Thus,
there was not a statistically significant difference in response rate between the two groups and therefore there was no benefit
from the addition of immunotherapy with rIL-2 to the standard chemotherapy. Both regimens were well tolerated. There were
2 toxic deaths (6.7%), 1 from hematological causes in group A and 1 from cardiac causes in group B. Myelosuppression and gastrointestinal
toxicity, mainly nausea/vomiting and stomatitis, were the most frequent toxicities. The calculated number of patients for
the sample has not yet been reached; however, the projection of our present results suggests that it is highly improbable
that a clinically significant difference between the two treatment groups will be observed even if the calculated patient
sample size is achieved.
Received: 9 April 1998 / Accepted: 30 June 1998 相似文献
933.
High amplitude and low frequency cyclic mechanical strain promotes degeneration of human nucleus pulposus cells via the NF‐κB p65 pathway 下载免费PDF全文
934.
935.
Xiaoling Zhang Qi Shen Bo Tang Huanhuan Liang Luhua Lai 《Protein science : a publication of the Protein Society》2016,25(11):2066-2075
De novo protein design offers templates for engineering tailor‐made protein functions and orthogonal protein interaction networks for synthetic biology research. Various computational methods have been developed to introduce functional sites in known protein structures. De novo designed protein scaffolds provide further opportunities for functional protein design. Here we demonstrate the rational design of novel tumor necrosis factor alpha (TNFα) binding proteins using a home‐made grafting program AutoMatch. We grafted three key residues from a virus 2L protein to a de novo designed small protein, DS119, with consideration of backbone flexibility. The designed proteins bind to TNFα with micromolar affinities. We further optimized the interface residues with RosettaDesign and significantly improved the binding capacity of one protein Tbab1‐4. These designed proteins inhibit the activity of TNFα in cellular luciferase assays. Our work illustrates the potential application of the de novo designed protein DS119 in protein engineering, biomedical research, and protein sequence‐structure‐function studies. 相似文献
936.
Hsin-Chih Lai Yu-Tze Horng Pen-Fang Yeh Jann-Yuan Wang Chin-Chung Shu Chia-Chen Lu Jang-Jih Lu Jen-Jyh Lee Po-Chi Soo 《Journal of microbiology (Seoul, Korea)》2016,54(11):761-767
Pulmonary tuberculosis (TB) is caused by Mycobacterium tuberculosis. The protein composition of sputum may reflect the immune status of the lung. This study aimed to evaluate the protein profiles in spontaneous sputum samples from patients with active pulmonary TB. Sputum samples were collected from patients with pulmonary TB and healthy controls. Western blotting was used to analyze the amount of interleukin 10 (IL-10), interferon-gamma (IFN-γ), IL-25, IL-17, perforin-1, urease, albumin, transferrin, lactoferrin, adenosine deaminase (also known as adenosine aminohydrolase, or ADA), ADA-2, granzyme B, granulysin, and caspase-1 in sputum. Results of detection of IL-10, IFN-γ, perforin-1, urease, ADA2, and caspase-1, showed relatively high specificity in distinguishing patients with TB from healthy controls, although sensitivities varied from 13.3% to 66.1%. By defining a positive result as the detection of any two proteins in sputum samples, combined use of transferrin and urease as markers increased sensitivity to 73.2% and specificity to 71.1%. Furthermore, we observed that the concentration of transferrin was proportional to the number of acid-fast bacilli detected in sputum specimens. Detection of sputum transferrin and urease was highly associated with pulmonary TB infection. In addition, a high concentration of transferrin detected in sputum might correlate with active TB infection. This data on sputum proteins in patients with TB may aid in the development of biomarkers to assess the severity of pulmonary TB. 相似文献
937.
W. Chen L. Huang J. Liang J. Cai Y. Lei J. Lai L. Liang K. Zhang 《European journal of histochemistry : EJH》2016,60(1)
Hilar cholangiocarcinoma (HCCA) is an invasive hepatic malignancy that is difficult to biopsy; therefore, novel markers of HCCA prognosis are needed. Here, the level of canonical Wnt activation in patients with HCCA, intrahepatic cholangiocarcinoma (IHCC), and congenital choledochal cysts (CCC) was compared to understand the role of Wnt signaling in HCCA. Pathology specimens from HCCA (n=129), IHCC (n=31), and CCC (n=45) patients were used to construct tissue microarrays. Wnt2, Wnt3, β-catenin, TCF4, c-Myc, and cyclin D1 were detected by immunohistochemistry. Parallel correlation analysis was used to analyze differences in protein levels between the HCCA, IHCC, and CCC groups. Univariate and multivariate analyses were used to determine independent predictors of successful resection and prognosis in the HCCA group. The protein levels of Wnt2, β-catenin, TCF4, c-Myc, and cyclin D1 were significantly higher in HCCA compared to IHHC or CCC. Wnt signaling activation (Wnt2+, Wnt3+, nuclear β-catenin+, nuclear TCF4+) was significantly greater in HCCA tissues than CCC tissues. Univariable analyses indicated that expression of cyclin D1 as well as Wnt signaling activation, and partial Wnt activation (Wnt2+ or Wnt3+ and nuclear β-catenin+ or nuclear TCF4+) predicted successful resection, but only cyclin D1 expression remained significant in multivariable analyses. Only partial Wnt activation was an independent predictor of survival time. Proteins in the canonical Wnt signaling pathway were present at higher levels in HCCA and correlated with tumor resecility and patient prognosis. These results suggest that Wnt pathway analysis may be a useful marker for clinical outcome in HCCA.Key words: Hilar cholangiocarcinoma, Wnt signaling pathway, tissue microarray, β-catenin, c-Myc, cyclin D1 相似文献
938.
939.
940.
Holly B. Kramer Chun-Fui Lai Hetal Patel Manikandan Periyasamy Meng-Lay Lin Stephan M. Feller Frances V. Fuller-Pace David W. Meek Simak Ali Laki Buluwela 《Nucleic acids research》2016,44(2):582-594
Liver receptor homologue 1 (LRH-1) is an orphan nuclear receptor that has been implicated in the progression of breast, pancreatic and colorectal cancer (CRC). To determine mechanisms underlying growth promotion by LRH-1 in CRC, we undertook global expression profiling following siRNA-mediated LRH-1 knockdown in HCT116 cells, which require LRH-1 for growth and in HT29 cells, in which LRH-1 does not regulate growth. Interestingly, expression of the cell cycle inhibitor p21 (CDKN1A) was regulated by LRH-1 in HCT116 cells. p21 regulation was not observed in HT29 cells, where p53 is mutated. p53 dependence for the regulation of p21 by LRH-1 was confirmed by p53 knockdown with siRNA, while LRH-1-regulation of p21 was not evident in HCT116 cells where p53 had been deleted. We demonstrate that LRH-1-mediated p21 regulation in HCT116 cells does not involve altered p53 protein or phosphorylation, and we show that LRH-1 inhibits p53 recruitment to the p21 promoter, likely through a mechanism involving chromatin remodelling. Our study suggests an important role for LRH-1 in the growth of CRC cells that retain wild-type p53. 相似文献